Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is a biotechnology company with a strong focus on research and development. The company leverages its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs that target viral infections and liver diseases. Based in Watertown, Massachusetts, Enanta is at the forefront of developing novel inhibitors aimed at combating the hepatitis C virus (HCV), among other conditions.
Enanta's portfolio includes several classes of direct-acting antiviral (DAA) inhibitors, such as protease inhibitors, NS5A inhibitors, and nucleotide polymerase inhibitors. These are complemented by a host-targeted antiviral (HTA) inhibitor class specifically designed against cyclophilin. One of the company's most notable achievements is the development of paritaprevir, a lead protease inhibitor that is a key component of AbbVie's approved HCV treatment regimen.
In addition to HCV, Enanta is actively pursuing treatments for other serious conditions. The company has a preclinical program targeting non-alcoholic steatohepatitis (NASH), a liver disease characterized by inflammation and damage due to fat buildup. Enanta's research also extends to hepatitis B and the respiratory syncytial virus (RSV), broadening its impact on viral and liver diseases.
Enanta operates in partnership with AbbVie, which markets its protease inhibitors, while other promising drug candidates are progressing through the development pipeline. The company's commitment to innovation and strategic collaboration positions it as a significant player in the biotech industry.
Enanta Pharmaceuticals (NASDAQ: ENTA) has completed a significant deal with OMERS, a major Canadian pension plan, selling 54.5% of its future royalty payments from AbbVie for $200 million. This agreement pertains to worldwide sales of MAVYRET®/MAVIRET®, effective from July 2023 to June 2032, with total payments capped at 1.42 times the purchase price. Enanta retains 45.5% of the royalties until the cap is reached. The funds from this transaction will support ongoing clinical development in Enanta's virology pipeline. The deal underscores the continuing value of MAVYRET®/MAVIRET® in treating chronic hepatitis C and strengthens Enanta's financial position without diluting shareholder equity.
Enanta Pharmaceuticals (NASDAQ: ENTA) recently presented preclinical data for its antiviral candidates EDP-235 and EDP-323 at the 33rd European Congress of Clinical Microbiology and Infectious Diseases. EDP-235, a 3CL protease inhibitor for SARS-CoV-2, showed superior tissue distribution and cell penetration, which may help address long COVID-19. It is undergoing evaluation in the Phase 2 SPRINT study, with topline data expected in May 2023. EDP-323, an L-protein inhibitor for RSV, demonstrated strong bioavailability and favorable pharmacokinetics, supporting once-daily oral dosing. A Phase 1 study of EDP-323 is ongoing, with results anticipated in Q2 2023. The company highlights ongoing clinical advancements and milestones aimed at developing effective therapies for viral infections.
Enanta Pharmaceuticals (NASDAQ:ENTA) has received Fast Track designation from the FDA for its L-protein inhibitor, EDP-323, aimed at treating respiratory syncytial virus (RSV). This designation highlights EDP-323's potential as an effective oral treatment for RSV, particularly for high-risk populations. In vitro studies show that EDP-323 has sub-nanomolar potency against RSV strains and is expected to be effective as a monotherapy or in combination with other treatments. The Fast Track program allows for expedited development, facilitating more frequent communication with the FDA. A Phase 1 clinical trial assessing EDP-323's safety and pharmacokinetics is underway. Promising preclinical data indicates significant RSV replication reduction and favorable oral bioavailability, suggesting it could become a leading oral antiviral therapy for RSV.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has announced the presentation of data for its leading antiviral candidates EDP-235 and EDP-323 at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from April 15-18, 2023, in Copenhagen. EDP-235 is a 3CL protease inhibitor aimed at treating COVID-19, while EDP-323 targets respiratory syncytial virus (RSV). Presentations will occur on April 17, with EDP-235's poster focusing on its potential for treating Long COVID, and EDP-323's poster detailing its pharmacokinetics. These developments underscore Enanta's commitment to advancing treatments for viral infections.
Enanta Pharmaceuticals (NASDAQ: ENTA) unveiled promising data on EDP-235 during the 36th International Conference on Antiviral Research in Lyon, France. EDP-235 showcases favorable safety, tolerability, and pharmacokinetics, supporting once-daily dosing without ritonavir. Preclinical studies suggest its potential to reduce COVID-19 transmission and viral rebound. The drug is currently in a Phase 2 trial (SPRINT) for non-hospitalized adults with mild to moderate COVID-19, with data expected in May 2023. Strong preclinical results highlight EDP-235's tissue penetration, and new non-nucleoside inhibitors were identified through high-throughput screening.
FAQ
What is the current stock price of Enanta Pharmaceuticals (ENTA)?
What is the market cap of Enanta Pharmaceuticals (ENTA)?
What is the focus of Enanta Pharmaceuticals?
Where is Enanta Pharmaceuticals located?
What are some of the diseases Enanta targets?
What is paritaprevir?
Does Enanta collaborate with other companies?
What is Enanta’s approach to drug discovery?
What is NASH?
What are DAAs?
What is an HTA inhibitor?
What makes Enanta significant in the biotech industry?
